Sandoz growth strategy in Japanese market - From Global Generics - - PowerPoint PPT Presentation

a Novartis company

Sandoz growth strategy in Japanese market

• From Global Generics company perspective -

IGPA Kyoto December 2012 Junichi Nakamichi, Country Head, Sandoz K.K.

2 | Sandoz Growth Strategy in Japanese Market | J. Nakamichi | IGPA Kyoto 2012

Agenda

Sandoz overview Leadership in differentiated generics Sandoz strategy for Japan

3 | Sandoz Growth Strategy in Japanese Market | J. Nakamichi | IGPA Kyoto 2012

Environment Patient needs Novartis portfolio

Sandoz is a Novartis Group Company

2011 sales

USD billion

Full range

• f

healthcare

• ptions

Innovative medicines Prevention Affordable

• ptions

Self-care Pharmaceuticals Sandoz – Generics Consumer Health (OTC, Animal Health) Vaccines and Diagnostics Eye Care (Alcon, CIBA VISION) 32.5 9.5 4.6 2.0 10.0

4 | Sandoz Growth Strategy in Japanese Market | J. Nakamichi | IGPA Kyoto 2012

Novartis’ mission is to care for and cure patients

In 2011, Novartis treated and protected more than 1 billion patients around the world with our products and Sandoz medicines reached over 400 million patients

5 | Sandoz Growth Strategy in Japanese Market | J. Nakamichi | IGPA Kyoto 2012

Sandoz sales grew at double-digit since 2009

Sandoz third-party sales

USD billion

+12% CAGR 2009 9.5 2010 8.6 2011 7.5

6 | Sandoz Growth Strategy in Japanese Market | J. Nakamichi | IGPA Kyoto 2012

2009 1940 1960 1980 2000 1886 Biochemie 1946 1986 1992 1946 Amifarma Sabex Durascan Roferm Azupharma Servipharm Geneva Multipharma Rolab CIBA Geigy 1859 1758 Hoechst fermentation Wyeth penicillins, Invamed, SBPA BASF Generics, Grandis, Labinca Apothecon, Lagap, Aventis cephalosporins 2003 2010

Sandoz roots in high-quality medicines run deep

2010 2012 2011

7 | Sandoz Growth Strategy in Japanese Market | J. Nakamichi | IGPA Kyoto 2012

Sandoz operates in 140 countries globally

Subsidiaries Representative

• ffices

* Sample Sandoz manufacturing and development sites.

Production* Development* Wilson Cambe/ Taboao Gebze Turbhe Strykow Zhongshan Kaminoyama Barleben Boucherville Broomfield Unterach Kalwe Holzkirchen Rudolstadt Kundl / Schaftenau Ljubljana / Mengeš Spartan Jakarta Candelaria

8 | Sandoz Growth Strategy in Japanese Market | J. Nakamichi | IGPA Kyoto 2012

Agenda

Sandoz strategy for Japan Sandoz overview Leadership in differentiated generics

9 | Sandoz Growth Strategy in Japanese Market | J. Nakamichi | IGPA Kyoto 2012

Sandoz has an industry-leading breadth of technologies

Inhalers Patches/ transdermals/ thin films Innovative solid formulations Implants Biosimilars API Cytotoxics Hormones Lyophilization Injectables Ophthalmics

Dermatology

10 | Sandoz Growth Strategy in Japanese Market | J. Nakamichi | IGPA Kyoto 2012

Sandoz is the global pioneer in safe, effective biosimilars

2006 2007 2009

• First biosimilar in EU;

approved May 2006

• Broad global launch (e.g.,

US, Japan & LATAM)

somatropin

• Introduced for nephrology

in Oct. 2007

• First EPO biosimilar in EU
• Launched in Oncology

(2009 & 2010)

erythropoietin

• Feb. 2009 EU approval
• Growing rapidly across

EU markets

G-CSF

2008 2010

11 | Sandoz Growth Strategy in Japanese Market | J. Nakamichi | IGPA Kyoto 2012

Sandoz is the world leader in developing, manufacturing and commercializing biosimilars

Commercial experience:

• Broad global presence (marketing in ~50 countries)

Manufacturing experience:

• Producing recombinant proteins since 1980
• Full range of capabilities

Development expertise:

• Pioneer – developing biosimilars since 1996
• 8-10 molecules in development, including mAbs

12 | Sandoz Growth Strategy in Japanese Market | J. Nakamichi | IGPA Kyoto 2012

Agenda

Sandoz strategy for Japan Leadership in differentiated generics Sandoz overview

13 | Sandoz Growth Strategy in Japanese Market | J. Nakamichi | IGPA Kyoto 2012

Sandoz Japan provides “Added-value” and “Trust through Reliability” by leveraging global assets

• API
• FDF* products
• Quality standards

Value-added products

• Onco-safe
• Pre-mixed /

liquid vials Addressing customer needs

• Difficult-to-make
• Biosimilars
• Globally integrated

drug safety management system

*Finished dosage forms

Differentiation Pursuing economies of scale People synergies

• Japan experts
• Diversified multi-

culture

• Talent

14 | Sandoz Growth Strategy in Japanese Market | J. Nakamichi | IGPA Kyoto 2012

API FDF* API sourcing Development FDF Production Inspection / Packaging

Local requirements For registration

Marketing

Global Japan

Support Partial Support Sharing reports QA Sales PMS

Business model deploying global scale merit

• Concept

*Finished dosage forms

15 | Sandoz Growth Strategy in Japanese Market | J. Nakamichi | IGPA Kyoto 2012

“We will be the main provider of high quality, affordable medicines helping secure long-term access to healthcare for people around the world.”

Sandoz mission